Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety evaluation for less restrictive discharge criteria for patients receiving high dose methotrexate

Katlin Fendler, Jennifer Rauscher, Patricia Galanis, Lindsay Wilde, Margaret Kasner, Gina Keiffer, Chetan Jeurkar, Ubaldo Martinez Outschoorn, Onder Alpdogan, Pierluigi Porcu, Michael Wysota, Beatrice Razzo, Adam Binder

Blood (2025) 146 (Supplement 1): 521.

https://doi.org/10.1182/blood-2025-521

Published: 2025

Journal Articles

Results of part 1 of a two-part study evaluating the combination of tazemetostat and CPX-351 (part 1) and palbociclib with CPX-351 (part 2) for the treatment of relapsed or refractory Acute Myeloid Leukemia

Gina Keiffer, Bruno Calabretta, Rossana Trotta, Svetlana Petruk, Alexander Mazo, Chetan Jeurkar, Lindsay Wilde, Margaret Kasner

Blood (2025) 146 (Supplement 1): 1686.

https://doi.org/10.1182/blood-2025-1686

Published: 2025

Journal Articles

Oral Decitabine-Cedazuridine: Adverse Effects and Tolerability in a Real-World, Multicenter Retrospective Study

Julia Palecki, Maya C. Rosenberg, Jason Chen, Xiaoying Zheng, Jun Han Choi, Niti Patel, Lindsay Wilde, Gina Keiffer, Catherine E. Lai, Margaret Kasner, Chetan Jeurkar

Blood (2024) 144 (Supplement 1): 6709.

https://doi.org/10.1182/blood-2024-206072

Published: 2024

Journal Articles

Initial Results of a Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Gina Keiffer, Lindsay Wilde, Chetan Jeurkar, Margaret Kasner, Neil D. Palmisiano

Blood (2024) 144 (Supplement 1): 6719.

https://doi.org/10.1182/blood-2024-210067

Published: 2024

Journal Articles

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Chetan Jeurkar, DO, Benjamin E Leiby, PhD, Joshua Banks, MS, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Joanne Filicko-O'Hara, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-133837

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Safety evaluation for less restrictive discharge criteria for patients receiving high dose methotrexate

Results of part 1 of a two-part study evaluating the combination of tazemetostat and CPX-351 (part 1) and palbociclib with CPX-351 (part 2) for the treatment of relapsed or refractory Acute Myeloid Leukemia

Oral Decitabine-Cedazuridine: Adverse Effects and Tolerability in a Real-World, Multicenter Retrospective Study

Initial Results of a Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Safety evaluation for less restrictive discharge criteria for patients receiving high dose methotrexate

Results of part 1 of a two-part study evaluating the combination of tazemetostat and CPX-351 (part 1) and palbociclib with CPX-351 (part 2) for the treatment of relapsed or refractory Acute Myeloid Leukemia

Oral Decitabine-Cedazuridine: Adverse Effects and Tolerability in a Real-World, Multicenter Retrospective Study

Initial Results of a Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only